{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:32:12Z","timestamp":1791484332176,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Pfizer, Inc. Dr. Gilbert's","award":["NINDS K23 NS 41920-01"],"award-info":[{"award-number":["NINDS K23 NS 41920-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Child &amp; Adolescent Psychiatry"],"published-print":{"date-parts":[[2003,8]]},"DOI":"10.1097\/01.chi.0000046897.27264.46","type":"journal-article","created":{"date-parts":[[2003,11,18]],"date-time":"2003-11-18T11:59:26Z","timestamp":1069156766000},"page":"902-907","source":"Crossref","is-referenced-by-count":33,"title":["Pharmacodynamics of Ziprasidone in Children and Adolescents: Impact on Dopamine Transmission"],"prefix":"10.1016","volume":"42","author":[{"given":"FLOYD R.","family":"SALLEE","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DONALD L.","family":"GILBERT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ALEXANDER A.","family":"VINKS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JEFFREY J.","family":"MICELI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LISA","family":"ROBARGE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KEITH","family":"WILNER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/01.CHI.0000046897.27264.46_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.ne.09.030186.002041","article-title":"Parallel organization of functionally segregated circuits linking basal ganglia and cortex","volume":"9","author":"Alexander","year":"1986","journal-title":"Annu Rev Neurosci"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib2","series-title":"Diagnostic and Statistical Manual for Psychiatry","author":"American Psychiatric Association","year":"1994"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib3","first-page":"A121","article-title":"Ropinirole for Tourette syndrome","volume":"56","author":"Anca","year":"2001","journal-title":"Neurology"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0165-1781(00)00108-6","article-title":"Diurnal variation in spontaneous eye-blink rate","volume":"93","author":"Barbato","year":"2000","journal-title":"Psychiatry Res"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib5","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF02245614","article-title":"The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography","volume":"124","author":"Bench","year":"1996","journal-title":"Psychopharmacologia"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib7","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/1531-8257(200011)15:6<1194::AID-MDS1019>3.0.CO;2-H","article-title":"Response to levodopa challenge in Tourette syndrome","volume":"15","author":"Black","year":"2000","journal-title":"Mov Disord"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4088\/JCP.v62n0111","article-title":"Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallel-group study","volume":"62","author":"Bruggeman","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib9","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1523\/JNEUROSCI.19-12-05044.1999","article-title":"OCD-like behaviors caused by a neuropotentiating transgene targeted to cortical and limbic D1+ neurons","volume":"19","author":"Campbell","year":"1999","journal-title":"J Neurosci"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib10","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/0006-3223(95)00315-0","article-title":"Blink rate in children with attention-deficit-hyperactivity disorder","volume":"39","author":"Caplan","year":"1996","journal-title":"Biol Psychiatry"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib11","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0733-8619(05)70324-8","article-title":"Future therapies of Tourette syndrome","volume":"15","author":"Chappell","year":"1997","journal-title":"Neurol Clin"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib12","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","article-title":"The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia","volume":"22","author":"David","year":"2000","journal-title":"Clin Ther"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","article-title":"Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial","volume":"22","author":"Dion","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib14","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archpsyc.1979.01780090065007","article-title":"Effects of dopamine agonists and antagonists in Tourette' s disease","volume":"36","author":"Feinberg","year":"1979","journal-title":"Arch Gen Psychiatry"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1212\/01.WNL.0000044058.64647.7E","article-title":"Tic reduction with pergolide in a randomized controlled trial in children","volume":"60","author":"Gilbert","year":"2003","journal-title":"Neurology"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib16","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.54.6.1310","article-title":"Tourette syndrome improvement with pergolide in a randomized, double-blind, crossover trial","volume":"54","author":"Gilbert","year":"2000","journal-title":"Neurology"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib17","first-page":"402","article-title":"Pergolide in the management of Tourette syndrome","volume":"12","author":"Griesemer","year":"1997","journal-title":"J Child Neurol"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/j.1875-9114.1998.tb03820.x","article-title":"The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone","volume":"18","author":"Hamelin","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0378-4347(95)00071-P","article-title":"Development and validation of a high-sensitivity assay for an antipsychotic agent, CP-88,059, with solid-phase extraction and narrow-bore high-performance liquid chromatography","volume":"668","author":"Janiszewski","year":"1995","journal-title":"J Chromatogr Biomed Appl"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib20","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1212\/WNL.34.5.677","article-title":"Blink rates and disorders of movement","volume":"34","author":"Karson","year":"1984","journal-title":"Neurology"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib21","first-page":"1211","article-title":"Differential effects of direct and indirect dopamine agonists on eye blink rate in cynomolgus monkeys","volume":"279","author":"Kleven","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib22","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/mds.870120320","article-title":"Dopamine agonist treatment of Tourette disorder in children: results of an open-label trial of pergolide","volume":"12","author":"Lipinski","year":"1997","journal-title":"Mov Disord"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0920-9964(91)90008-F","article-title":"Increased blink rates in schizophrenics: influences of neuroleptics and psychopathology","volume":"4","author":"Mackert","year":"1991","journal-title":"Schizophrenia Res"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s004060170049","article-title":"Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol","volume":"251","author":"Markianos","year":"2001","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1089\/104454601317261564","article-title":"Prolactin levels in young children with pervasive developmental disorders during risperidone treatment","volume":"11","author":"Masi","year":"2001","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"suppl","key":"10.1097\/01.CHI.0000046897.27264.46_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1046\/j.1365-2125.2000.00147.x","article-title":"Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers","volume":"49","author":"Miceli","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"suppl","key":"10.1097\/01.CHI.0000046897.27264.46_bib27","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2125.2000.00153.x","article-title":"Ziprasidone and the pharmacokinetics of a combined oral contraceptive","volume":"49","author":"Muirhead","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0006-3223(00)00850-7","article-title":"5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex","volume":"48","author":"Rollema","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib29","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004583-200003000-00010","article-title":"Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study","volume":"39","author":"Sallee","year":"2000","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib30","first-page":"101","article-title":"Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity","volume":"275","author":"Seeger","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib31","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0733-8619(05)70318-2","article-title":"Neurobiology of Tourette syndrome","volume":"15","author":"Singer","year":"1997","journal-title":"Neurol Clin"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1006\/exnr.1999.7093","article-title":"Spontaneous blink rates correlate with dopamine levels in the caudate nucleus of MPTP-treated monkeys","volume":"158","author":"Taylor","year":"1999","journal-title":"Exp Neurol"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","article-title":"Treatment of ADHD in children with tics","volume":"58","author":"Tourette Syndrome Study Group","year":"2002","journal-title":"Neurology"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib34","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/jnnp.67.6.800","article-title":"Quantitative study of spontaneous eye blinks and eye tics in Gilles de la Tourette's syndrome","volume":"67","author":"Tulen","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0304-3940(96)12575-1","article-title":"Enhancement of human motor cortex inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation","volume":"208","author":"Ziemann","year":"1996","journal-title":"Neurosci Lett"},{"key":"10.1097\/01.CHI.0000046897.27264.46_bib36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0924-980X(97)00050-7","article-title":"Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs","volume":"105","author":"Ziemann","year":"1997","journal-title":"Electroencephalogr Clin Neurophysiol"}],"container-title":["Journal of the American Academy of Child &amp; Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856709610959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856709610959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T07:14:24Z","timestamp":1704957264000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856709610959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["S0890856709610959"],"URL":"https:\/\/doi.org\/10.1097\/01.chi.0000046897.27264.46","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2003,8]]}}}